AR127311A1 - NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 - Google Patents

NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2

Info

Publication number
AR127311A1
AR127311A1 ARP220102740A ARP220102740A AR127311A1 AR 127311 A1 AR127311 A1 AR 127311A1 AR P220102740 A ARP220102740 A AR P220102740A AR P220102740 A ARP220102740 A AR P220102740A AR 127311 A1 AR127311 A1 AR 127311A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
formula
artificial nucleic
cov
sars
Prior art date
Application number
ARP220102740A
Other languages
Spanish (es)
Inventor
Xishan Lu
Bo Ying
Original Assignee
Suzhou Abogen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Abogen Biosciences Co Ltd filed Critical Suzhou Abogen Biosciences Co Ltd
Publication of AR127311A1 publication Critical patent/AR127311A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)

Abstract

Moléculas de ácido nucleico terapéutico para gestionar, prevenir y/o tratar enfermedades infecciosas causadas por el coronavirus. También composiciones terapéuticas, que incluyen vacunas y nanopartículas lipídicas, que comprenden los ácidos nucleicos terapéuticos y los métodos y usos terapéuticos relacionados. En particular, vacunas de ARNm basadas en secuencias derivadas de la cepa delta del SARS-CoV-2. Reivindicación 1: Un ácido nucleico artificial caracterizado porque comprende una secuencia de nucleótidos codificante que codifica el dominio de unión al receptor (RBD) de la proteína de la espícula (S) de la cepa delta del SARS-CoV-2, o un fragmento de la misma, en donde el RBD consiste, consiste esencialmente o comprende la secuencia de aminoácidos establecida en SEQ ID Nº 60. Reivindicación 11: Un vector caracterizado porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10. Reivindicación 12: Una célula caracterizada porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10 o el vector de la reivindicación 11. Reivindicación 13: Una composición farmacéutica caracterizada porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10 y al menos un primer lípido, en donde el primer lípido es un compuesto de acuerdo con la fórmula (01-I) o (01-II); o un compuesto enumerado en la Tabla 01-1; o un compuesto de acuerdo con la fórmula (02-I); o un compuesto enumerado en la Tabla 02-1; o un compuesto de acuerdo con la fórmula (03-I); o un compuesto enumerado en la Tabla 03-1; o un compuesto de acuerdo con la fórmula (04-I); o un compuesto enumerado en la Tabla 04-1. Reivindicación 17: Un método para gestionar, prevenir o tratar una enfermedad infecciosa causada por coronavirus en un sujeto, caracterizado porque comprende administrar al sujeto una cantidad terapéuticamente eficaz del ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10, o la composición de cualquiera de las reivindicaciones 13 a 16.Therapeutic nucleic acid molecules to manage, prevent and/or treat infectious diseases caused by coronavirus. Also therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses. In particular, mRNA vaccines based on sequences derived from the delta strain of SARS-CoV-2. Claim 1: An artificial nucleic acid characterized in that it comprises a coding nucleotide sequence that encodes the receptor binding domain (RBD) of the spike (S) protein of the delta strain of SARS-CoV-2, or a fragment of the same, wherein the RBD consists, essentially consists of or comprises the amino acid sequence set forth in SEQ ID NO: 60. Claim 11: A vector characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10. Claim 12: A cell characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10 or the vector of claim 11. Claim 13: A pharmaceutical composition characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10 and at least one first lipid , wherein the first lipid is a compound according to the formula (01-I) or (01-II); or a compound listed in Table 01-1; or a compound according to the formula (02-I); or a compound listed in Table 02-1; or a compound according to the formula (03-I); or a compound listed in Table 03-1; or a compound according to the formula (04-I); or a compound listed in Table 04-1. Claim 17: A method of managing, preventing or treating an infectious disease caused by coronavirus in a subject, characterized in that it comprises administering to the subject a therapeutically effective amount of the artificial nucleic acid of any of claims 1 to 10, or the composition of any of claims 13 to 16.

ARP220102740A 2021-10-08 2022-10-06 NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 AR127311A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021122702 2021-10-08
CN2022118782 2022-09-14

Publications (1)

Publication Number Publication Date
AR127311A1 true AR127311A1 (en) 2024-01-10

Family

ID=85803170

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102740A AR127311A1 (en) 2021-10-08 2022-10-06 NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2

Country Status (3)

Country Link
CN (1) CN117083291A (en)
AR (1) AR127311A1 (en)
WO (1) WO2023056913A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11141476B2 (en) * 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
US20200054737A1 (en) * 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
EP4103228A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CN111393532B (en) * 2020-02-26 2021-10-12 北京丹大生物技术有限公司 Novel coronavirus dominant epitope fusion protein, diagnostic reagent and application
CN111218458B (en) * 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 mRNAs encoding SARS-CoV-2 virus antigen and vaccine and preparation method of vaccine
CN113151312B (en) * 2020-03-02 2022-12-09 中国科学院微生物研究所 Novel coronavirus SARS-CoV-2mRNA vaccine and its preparation method and application
CA3170575A1 (en) * 2020-03-06 2021-09-10 Michael Gordon Joyce Vaccines against sars-cov-2 and other coronaviruses
CN112979483B (en) * 2021-05-14 2021-08-06 苏州艾博生物科技有限公司 Cationic lipid compound, composition containing same and application
CN113018449B (en) * 2021-05-14 2021-09-07 苏州艾博生物科技有限公司 Cationic lipid compounds, compositions containing the same and uses thereof
CN113046369B (en) * 2021-05-24 2021-08-10 中国科学院微生物研究所 Novel mRNA vaccine of coronavirus

Also Published As

Publication number Publication date
WO2023056913A1 (en) 2023-04-13
CN117083291A (en) 2023-11-17

Similar Documents

Publication Publication Date Title
JP5813778B2 (en) Immunomodulatory oligonucleotide (IRO) compounds for modulating immune responses based on toll-like receptors
JP2016522674A (en) Compositions and methods for regulating gene expression
JP2015523854A (en) Compositions and methods for modulating SMN gene family expression
AR081295A1 (en) TREATMENT OF DISEASES RELATED TO LIM HOMEOBOX 2 (LHX2) THROUGH THE INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO POLINUCLEOTIDES LHX2
JP2017504589A5 (en)
AU2018247308A1 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2023145532A (en) Treatment of local skin hypotrophy conditions
Wang et al. Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy
JP5981141B2 (en) Use of interleukin-22 for prevention and / or treatment of multiple organ dysfunction syndrome (MODS)
AR127858A1 (en) NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2
AR125351A1 (en) COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF PNPLA3
AR127311A1 (en) NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2
EP3638292A1 (en) Polynucleotides encoding coagulation factor viii
WO2015037001A1 (en) Methods for inducing glucose uptake
EP2897633B1 (en) Treatment of pain by inhibition of usp5 de-ubiquitinase
JP2017525675A5 (en)
WO2019161294A1 (en) Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm)
KR101674122B1 (en) Prevention or Treatment for ischemic stroke using miR-135-5p
JPWO2015162930A1 (en) Method for improving protein expression and composition for protein expression
TWI846697B (en) Engineered extracellular vesicles and uses thereof
WO2010038965A2 (en) GCH1-TARGETED si RNA, RECOMBINANT VECTOR CONTAINING si RNA, AND PHARMACEUTICAL COMPOSITION CONTAINING RECOMBINANT VECTOR FOR TREATING AND PREVENTING NEUROPATHIC PAIN
WO2022170396A1 (en) Agents and methods for therapy and prophylaxis
JP2016020323A (en) Composition for scaffold material for nerve regeneration
AR122471A1 (en) NEW ANKYRINE REPEAT-BINDING PROTEINS AND THEIR USES
AR123724A1 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19

Legal Events

Date Code Title Description
FB Suspension of granting procedure